TIDMPRTC
PureTech Health PLC
12 December 2022
12 December 2022
PureTech Presents Data for LYT-200 Targeting Galectin-9 in
Preclinical Leukemia Cancer Models at the 64(th) American Society
of Hematology (ASH) Annual Meeting
Data support the role of galectin-9 in multiple types of
leukemia and the ability of anti-galectin-9 antibodies to provide
effective anti-tumor activity in these cancers
Clinical trial has initiated evaluating LYT-200 as a single
agent in acute myeloid leukemia (AML) patients
LYT-200 is also being evaluated in a range of metastatic solid
tumors as a monotherapy and in combination with chemotherapy or an
anti-PD-1 antibody; the first part of the Phase 1 trial has
completed, with the combination part beginning in the first quarter
of 2023
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
changing the treatment paradigm for devastating diseases, today
shared new data supporting the clinical potential of LYT-200, a
fully human monoclonal antibody (mAb) designed to inhibit the
activity of galectin-9, as a therapeutic agent for the treatment of
leukemia. The data were shared in a scientific poster presented at
the American Society of Hematology (ASH) 64(th) Annual Meeting.
LYT-200 is a therapeutic candidate targeting galectin-9, which is
expressed by tumors and immune cells and plays a key role in cancer
treatment resistance. It is also in development as a treatment for
a range of cancer indications with otherwise poor survival
rates.
"The data we are presenting at ASH add further support to the
hypothesis that galectin-9 is an important therapeutic target for
not just AML but multiple blood cancers, suggesting LYT-200 may be
beneficial across a range of hematologic malignancies and
underscores the potential of LYT-200 in an area with significant
clinical need for novel treatment regimens," said Aleksandra
Filipovic, M.D., Ph.D., Head of Oncology at PureTech. "The National
Cancer Institute estimates that about 61,000 new cases of leukemia
are diagnosed each year, including about 20,000 in AML. More than
50% of AML patients either don't respond to initial treatment or
experience relapse or death after responding to initial treatment,
and have an approximately 12.6% five-year survival rate . The poor
overall survival highlights the need for more effective therapies
for patients with relapsed and refractory AML."
The ASH poster evaluates galectin-9 expression and the effects
of LYT-200 in multiple types of leukemia. Compared to healthy human
peripheral blood mononuclear cells, where galectin-9 surface
expression was low or absent, galectin-9 was highly expressed on
the surface of all human blood cancer cells tested. Notably,
surface expression of galectin-9 often exceeded that of the known
inhibitory checkpoint proteins TIM-3 and PD-1.
In all models used, LYT-200 demonstrated significant anti-tumor
activity and in addition to its established effects on the immune
system in solid tumor models, it also notably induced direct
apoptosis or cell death across all leukemia cell types. In a model
assessing DNA damage in AML cells, LYT-200 significantly
outperformed an anti-TIM3 antibody and had effects that were
comparable to Venetoclax, an approved therapeutic for AML. The
effects were greatest when both compounds were combined. The in
vitro efficacy of LYT-200 against the leukemia subtypes also
extended to in vivo survival benefit in both immunocompromised and
immunocompetent patient-derived xenograft mouse models. In these
models, LYT-200 outperformed chemotherapy and produced the greatest
effect in combination.
Collectively, these new data support galectin-9 as a strong
potential therapeutic target for a range of cancers. Based on this
and other compelling preclinical data generated with LYT-200 in
blood cancers, PureTech has initiated a clinical trial to evaluate
LYT-200 as a single agent for the treatment of AML with results
expected in 2023. PureTech has also completed the bi-monthly and
weekly, monotherapy dose escalation portion of the Phase 1 program
assessing the safety and tolerability of escalating doses of
LYT-200 as a potential treatment of metastatic solid tumors. No
dose-limiting toxicities were reported, and the full results will
be presented in an upcoming scientific forum. The combination part
of the Phase 1 trial in certain metastatic solid tumors with
LYT-200 in combination with tislelizumab is expected to begin in
the first quarter of 2023.
The scientific poster presented today is available at
https://puretechhealth.com/LYT-200-ASH-2022-poster .
About LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody targeting a
foundational immunosuppressive protein, galectin-9, for the
potential treatment of solid tumors, including pancreatic ductal
adenocarcinoma, colorectal cancer and cholangiocarcinoma, with
otherwise poor survival rates. A wide variety of preclinical data
supports the potential clinical efficacy of LYT-200 and the
importance of galectin-9 as a target and suggests a potential
opportunity for biomarker development. For example, PureTech has
presented data demonstrating high expression of galectin-9 across
various solid tumor types and blood cancers and has found in
several cancers that galectin-9 levels correlate with shorter time
to disease relapse and poor survival. LYT-200 is currently being
evaluated in a Phase 1/2 adaptive design trial for the potential
treatment of metastatic solid tumors and in a clinical trial for
the potential treatment of AML .
About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the
treatment paradigm for devastating diseases. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 28 therapeutics and therapeutic
candidates, including two (Plenity(R) and EndeavorRx(R)) that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that will soon be filed for FDA
approval, as of the most recent update by the Company. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation those
statements related to LYT-200, its development, clinical milestones
and potential therapeutic applications, our presentation at the
American Society of Hematology, and our future prospects,
developments, and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2021 filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFWEDFEESEEE
(END) Dow Jones Newswires
December 12, 2022 09:00 ET (14:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024